Inactive Instrument

Provexis plc Stock CINNOBER BOAT

Equities

PXS

GB00B0923P27

Food Processing

Sales 2022 426K 534K Sales 2023 390K 489K Capitalization 17.52M 21.96M
Net income 2022 - 0 Net income 2023 - 0 EV / Sales 2022 42.1 x
Net cash position 2022 864K 1.08M Net cash position 2023 379K 475K EV / Sales 2023 44 x
P/E ratio 2022
-84.2 x
P/E ratio 2023
-39.7 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 78.57%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer - 07-07-18
Chief Tech/Sci/R&D Officer 50 99-12-31
Members of the board TitleAgeSince
Chairman 77 04-12-31
Chief Executive Officer - 07-07-18
Chief Tech/Sci/R&D Officer 50 99-12-31
More insiders
Provexis plc is engaged in developing, licensing and selling the proprietary, scientifically proven Fruitflow heart-health functional food ingredient. Fruitflow is a natural extract from tomatoes, which has been shown in human trials to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can lead to heart attack and stroke. The extract is available in two formats, a syrup and a spray-dried powder and can be included in a range of food, beverage, and dietary supplement formats. Fruitflow is a highly concentrated form of bioactives that is lycopene-free and contains over 30 known anti-platelet compounds. The syrup and powder versions of Fruitflow are GRAS in the United States. The Company also offers Fruitflow+ Omega-3, a dietary supplement product. The Company sells its Fruitflow+ Omega-3 dietary supplement product direct to consumers and serves its Chinese cross-border e-commerce distributor for this product in China.
More about the company